Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl-1,4-dihydropyridines as selective A3 adenosine receptor antagonists

被引:57
作者
Jiang, JL
Li, AH
Jang, SY
Chang, L
Melman, N
Moro, S
Ji, XD
Lobkovsky, EB
Clardy, JC
Jacobson, KA
机构
[1] NIDDKD, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA
[2] Cornell Univ, Baker Lab, Dept Chem, Ithaca, NY 14853 USA
关键词
D O I
10.1021/jm980688e
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Racemic 6-phenyl-4-phenylethynyl-1,4-dihydropyridine derivatives have been shown to be highly selective A(3) adenosine receptor antagonists (Jiang et al. J. Med. Chem. 1997, 40, 2596-2608). Methods for resolving the optical isomers at the C4 position, involving selective crystallization or chromatographic separation of diastereomeric ester derivatives, have been developed. Optically pure glycerol and threitol derivatives were used as chiral auxiliary groups for ester formation at the 3-position, resulting in diastereomeric mixtures of dihydropyridines. Esterification of a 6-phenyl-4-phenylethynyl-1,4-dihydropyridine derivative at the S-position with a chiral, protected glycerol moiety, (S)-(+)-2,2-dimethyl-1,3-dioxolane-4-methanol, allowed the selective crystallization of a pure diastereomer, 9. The H-1 NMR spectrum of 9 using the lanthanide shift reagent Eu(fod)(3) indicated optical purity, and the (4S,2'R)-configuration was assigned using X-ray crystallography. The noncrystalline (4R,2'R)-isomer 10 was also isolated and shown to be 3-fold more potent than the (4S,2'R)-isomer in binding to A(3) receptors. The 2,2-dimethyl-1,3-dioxolane moiety also served as a protected form of a diol, which showed selective reactivity versus a 5-ethyl ester in basic transesterification reactions. A racemic 5-carboxylic acid derivative could not be resolved through crystallization of diastereomeric salts. Enantiomers of 5-benzyl 3-ethyl 2-methyl-6-phenyl-4-phenylethynyl-1,4-dihydropyridine-3,5-dicarboxylate (2) were obtained via an ester derived from (4R,5R)-(-)-2,3-O-isopropylidene-D-threitol at the 3-position, which was resolved using HPLC, and each diastereomer was subsequently deprotected in acidic conditions. The resulting diols were exchanged for ethyl ester groups by base-catalyzed transesterification. The binding of pure enantiomers of 2 at A(3) adenosine receptors indicated a 35-fold stereoselectivity for the (4S)-isomer 21. A receptor docking hypothesis, using a previously derived human A(3) receptor model, shows the bulkier of the two ester groups (5-Bn) of 21 oriented toward the exofacial side and the 4-position phenylethynyl group situated between transmembrane helical domain TM6 and TM7.
引用
收藏
页码:3055 / 3065
页数:11
相关论文
共 36 条
[1]  
BEAVEN MA, 1994, TRENDS PHARMACOL SCI, V15, P13, DOI 10.1016/0165-6147(94)90124-4
[2]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[3]   1,4-DIHYDROPYRIDINE ANTAGONIST ACTIVITIES AT THE CALCIUM-CHANNEL - A QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP APPROACH [J].
COBURN, RA ;
WIERZBA, M ;
SUTO, MJ ;
SOLO, AJ ;
TRIGGLE, AM ;
TRIGGLE, DJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (11) :2103-2107
[4]   THE DEVELOPMENT AND USE OF QUANTUM-MECHANICAL MOLECULAR-MODELS .76. AM1 - A NEW GENERAL-PURPOSE QUANTUM-MECHANICAL MOLECULAR-MODEL [J].
DEWAR, MJS ;
ZOEBISCH, EG ;
HEALY, EF ;
STEWART, JJP .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1985, 107 (13) :3902-3909
[5]   1,4-DIHYDROPYRIDINES - EFFECTS OF CHIRALITY AND CONFORMATION ON THE CALCIUM-ANTAGONIST AND CALCIUM AGONIST ACTIVITIES [J].
GOLDMANN, S ;
STOLTEFUSS, J .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION IN ENGLISH, 1991, 30 (12) :1559-1578
[6]   STEREOISOMERS OF CALCIUM-ANTAGONISTS WHICH DIFFER MARKEDLY IN THEIR POTENCIES AS CALCIUM BLOCKERS ARE EQUALLY EFFECTIVE IN MODULATING DRUG TRANSPORT BY P-GLYCOPROTEIN [J].
HOLLT, V ;
KOUBA, M ;
DIETEL, M ;
VOGT, G .
BIOCHEMICAL PHARMACOLOGY, 1992, 43 (12) :2601-2608
[7]   Adenosine A3 receptors:: novel ligands and paradoxical effects [J].
Jacobson, KA .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, 19 (05) :184-191
[8]  
JACOBSON MA, 1996, DRUG DEVELOP RES, V37, P131
[9]  
JARVIS MF, 1989, J PHARMACOL EXP THER, V251, P888
[10]   SPECIES-DIFFERENCES IN LIGAND AFFINITY AT CENTRAL A(3)-ADENOSINE RECEPTORS [J].
JI, XD ;
VONLUBITZ, D ;
OLAH, ME ;
STILES, GL ;
JACOBSON, KA .
DRUG DEVELOPMENT RESEARCH, 1994, 33 (01) :51-59